Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Prototype Kit Diagnoses Visceral Leishmaniasis

By LabMedica International staff writers
Posted on 07 May 2013
A prototype direct agglutination test (DAT) kit for the laboratory diagnosis of visceral leishmaniasis (VL), called DAT-LPC, has been developed. More...


The diagnosis validity of this prototype DAT-LPC, which uses a freeze-dried antigen, was performed to evaluate the sensitivity and specificity of the assay.

Scientists at the Oswaldo Cruz Foundation (FIOCRUZ; Belo Horizonte, Brazil) took blood samples from 103 Brazilian patients with VL and 110 samples from patients with other parasitic infections, and healthy subjects. These samples were assayed with DAT-LPC and DAT-KIT (Royal Tropical Institute; Amsterdam, NL). Additionally, the results of 103 samples of VL patients based on two agglutination tests were correlated.

The DAT-LPC was incubated for four hours at room temperature; the end titer was read as the dilution immediately before the well with a clear sharp-edged blue spot identical in size to the reaction negative control. Appropriate negative and positive control samples with known DAT titers were included. The cut-off for interpretation of positive and negative results was 1:100. The DAT-LPC showed a sensitivity of 99.0%, specificity of 98.2% and diagnosis validity of 98.6%, which were similar to those found by the DAT-KIT. Moreover, there was positive correlation between the positive titers obtained by DAT-LPC and by DAT-KIT.

After six months of storage in an incubator at 40 °C and 75% moisture the DAT-LPC prototype remained stable. Physical aspects remained the same, and it produced consistent results with negative and positive samples assayed monthly. The authors concluded that the prototype kit showed high diagnostic accuracy and thermal stability; it is ready for use and could be transferred to industrial production. The DAT-LPC should replace the indirect immunofluorescent antibody test (IFAT) in routine serological tests for VL diagnosis in Brazil. It could be used in a complementary algorithm with immunochromatic dipstick tests, for different clinical scenarios and laboratorial settings. The study was published on February 3, 2013, in the journal Transactions of The Royal Society of Tropical Medicine and Hygiene.

Related Links:

Oswaldo Cruz Foundation
Royal Tropical Institute



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.